Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy
|発行||CBR Pharma Insights||商品コード||274485|
|生物薬剤のM&A・契約形成：将来の戦略を最適化するための最新動向の理解 Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy|
|出版日: 2013年03月01日||ページ情報: 英文||
The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size of deals year by year. This in itself, along with the rising financial firepower of the mid-tier players, has increased the level of competition for the most attractive targets.
Increased competition in the marketplace for M&A and licensing deals can artificially inflate the cost of these deals, distorting the balance of value, risk and return. As a result companies must employ more rigorous selection processes and expand search criteria to consider more diverse options if they are to maximize their returns on investment.
The report, “Biopharma M&A and Deal Making”, was written to support team and corporate strategic initiatives around the options that exist to grow revenues through externalization, whether by M&A or licensing. CBR Pharma Insights provides in-depth analysis on the deals being done today, the trends being seen over time, and the strategies employed throughout the industry.